Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Accumulated Expenses (2022 - 2025)

Historic Other Accumulated Expenses for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $4.8 million.

  • Phathom Pharmaceuticals' Other Accumulated Expenses rose 16731.73% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 16731.73%. This contributed to the annual value of $3.0 million for FY2024, which is 250170.94% up from last year.
  • Phathom Pharmaceuticals' Other Accumulated Expenses amounted to $4.8 million in Q3 2025, which was up 16731.73% from $4.9 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Other Accumulated Expenses' 5-year high stood at $4.9 million during Q2 2025, with a 5-year trough of $20000.0 in Q3 2023.
  • Its 4-year average for Other Accumulated Expenses is $1.3 million, with a median of $151000.0 in 2022.
  • As far as peak fluctuations go, Phathom Pharmaceuticals' Other Accumulated Expenses plummeted by 4615.38% in 2023, and later surged by 886500.0% in 2024.
  • Over the past 4 years, Phathom Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $151000.0 in 2022, then fell by 22.52% to $117000.0 in 2023, then soared by 2501.71% to $3.0 million in 2024, then soared by 57.46% to $4.8 million in 2025.
  • Its last three reported values are $4.8 million in Q3 2025, $4.9 million for Q2 2025, and $2.8 million during Q1 2025.